Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2017 01/12/2017 01/13/2017 01/17/2017 01/18/2017 Date
81.93(c) 82.39(c) 83.17(c) 81.55(c) 82.43 Last
2 785 209 1 351 806 1 518 581 1 501 513 335 649 Volume
-1.21% +0.56% +0.95% -1.95% +1.08% Change
More quotes
Financials ($)
Sales 2016 1 694 M
EBIT 2016 208 M
Net income 2016 -134 M
Finance 2016 502 M
Yield 2016 -
Sales 2017 2 102 M
EBIT 2017 494 M
Net income 2017 196 M
Finance 2017 760 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 110,40
EV / Sales2016 11,6x
EV / Sales2017 9,26x
Capitalization 20 227 M
More Financials
Company
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including... 
More about the company
Surperformance© ratings of Vertex Pharmaceuticals Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERTEX PHARMACEUTICALS INC
01/14 VERTEX PHARMACEUTICALS INCORPORATED : Merck expands oncology portfolio with four..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Announces Upcoming Presentation at the J.P..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Patent Issued for Methods of Regioselectiv..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Entry into a Material ..
01/11 VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement (fo..
01/11 VERTEX PHARMACEUTICALS INCORPORATED : Merck KGaA, Darmstadt, Germany Licenses Fo..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : VRTX) Files An 8-K Results of Operations ..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : INC / MA Results of Operations and Financi..
01/09 VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
01/09 VERTEX PHARMACEUTICALS INCORPORATED : Pharma Provides Update On Business And Fin..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/17Concert Pharma to add additional step in mid-stage study of CF candidate CTP-.. 
01/17Nice lil' writeup this AM by Yeezus: Trump headlines on 'drug pricing' - shou..
9
01/17Ian Smith said black people won't rule Zimbabwe in 1000 years. Look where tha..
14
01/12Vertex Pharmaceuticals Incorporated downgraded by Zacks Investment Research t.. 
01/12Watch These 8 Huge Call Purchases In Thursday Trade
2
More tweets
Qtime:78
News from SeekingAlpha
01/17 Concert Pharma to add additional step in mid-stage study of CF candidate CTP-..
01/13 2016 : A Record Year
01/12 Vertex And German Merck Find Their Perfect Fit
01/12 JPMorgan Day Three Roundup - Trump Reminds The Sector Who's In Charge
01/11 Vertex to collaborate with Germany's Merck in oncology
Advertisement
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,4 $
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..10.70%20 227
AMGEN, INC.5.88%115 159
GILEAD SCIENCES, INC.0.42%94 738
CELGENE CORPORATION-0.69%89 110
REGENERON PHARMACEUTIC..-1.05%38 311
ACTELION LTD4.58%24 564
More Results